about participate agendas faculty cme info contact

BUILDING BRIDGES to BrIng AntiamyloiD Monoclonal Antibodies to EliGible PatiEnts With Alzheimer’s Disease

With recent approvals of antiamyloid monoclonal antibodies (mAbs), the field of Alzheimer’s disease (AD) is rapidly changing. Implementation of these therapies requires new protocols and workflows in clinics, including collaboration among multiple departments. This grassroots initiative consists of a 2-part series of live, on-site meetings for neurology and radiology clinicians, as well as emergency department and infusion center staff. Prior to the live meeting, a site survey will assess current practices to tailor content to each location. Drs. Lawrence Honig and David Weisman will discuss details of antiamyloid mAbs, collaboration and communication tips, and best practices for developing implementation protocols. They will also help troubleshoot each location’s protocol development. Participating locations will receive numerous handouts, checklists, and other resources that will aid in development and implementation of these novel protocols and in patient education around these therapies.

Request a live, 2-part CME workshop for your institution:

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form :(

Workshop agendas

WORKSHOP 1 Agenda

Laying the Foundation for Administering Antiamyloid mAbs for Patients With Early AD

  • An introduction to antiamyloid mAbs
  • A review of FDA-approved antiamyloid mAbs
  • Patient selection criteria for antiamyloid mAbs
  • Proving early AD diagnosis: CSF and PET scans
  • CMS registry requirements
  • Preparing to manage adverse events
  • Understanding ARIA: occurrence, risks, and types
  • APOE4 genetic testing
  • Routine MRI monitoring and key identifiers for radiology
  • Adjusting dosages or stopping medication due toARIA
  • Could it be ARIA: lessons for emergency department clinicians and infusion center staff
  • Infusion site reactions: what infusion center staff need to know
  • Overview of staffing and workflow requirements to administer antiamyloid mAbs
  • Q&A: group discussion about individual practice needs and challenges to initial steps in clinic protocol development (this discussion will help form the content for Workshop #2)

WORKSHOP 2 Agenda

(scheduled approximately 1 month after Workshop #1)

Overcoming Hurdles to Antiamyloid mAb Clinic Protocol Development

  • Coordinating care teams
  • Individual roles of the multidisciplinary care team members
  • Improving communication and role of EMR
  • Patient and caregiver education
  • Who is responsible for delivering education?
  • Establishing communication pathways with clinicians
  • Establishing protocol checklists: before, during, and after infusion
  • Exploring financial aspects of antiamyloid mAbs
  • Q&A and individualized troubleshooting: discussion may include site-specific challenges regarding interdepartmental communication, protocol checklists, scheduling or administrative barriers, or strategies for communicating with key decision-makers

faculty

Lawrence S. Honig, MD, PhD photo

Lawrence S. Honig, MD, PhD‍

Professor of Neurology, Columbia University Irving Medical Center
Director, NYS Center of Excellence for Alzheimer’s Disease
Taub Institute for Research on Alzheimer's Disease and the Aging Brain
Gertrude H. Sergievsky Center (PH19)
Department of Neurology
Columbia University Vagelos College of Physicians & Surgeons
New York, New York

David C. Weisman, MD Photo

David C. Weisman, MD‍

Director, ANA Clinical Trial Center
Abington Neurological Associates
Abington, Pennsylvania

ACCREDITATION INFORMATION

Participants who attend both live workshops will receive up to 2.0 CME/CE credit (1.0 CME/CE for each workshop)

Target Audience

The educational design of this activity addresses the needs of neurology, radiology, emergency, geriatric, and primary care clinicians, and infusion center staff (physicians, nurse practitioners, physician assistants, nurses, and administrative staff) who are involved in the management of patients with AD.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

  • Identify patients eligible for treatment with antiamyloid mAbs
  • Review strategies to identify and address adverse events associated with antiamyloid mAbs
  • Describe necessary components of clinic protocols for administering antiamyloid mAbs
  • Establish interdepartmental communication regarding administration of antiamyloid mAbs, routine monitoring, and management of adverse events

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates these live activities for a maximum of 1.0 AMA PRA Category 1 Credit™ each, for a total of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Nurses Credentialing Center’s (ANCC) Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live meeting and complete the posttest and program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the ACCME and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Americans With Disabilities Act

🦽 Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact us prior to the live event at info@exchangecme.com.

This activity is provided by Integritas Communications.

This activity is supported by an educational grant from Eisai Inc.

For additional CME/CE opportunities, please visit www.ExchangeCME.com.